Alisa Beth Goldberg, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 39 | 2023 | 458 | 9.220 |
Why?
|
| Misoprostol | 20 | 2023 | 95 | 7.520 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 16 | 2023 | 62 | 5.310 |
Why?
|
| Mifepristone | 14 | 2023 | 150 | 2.850 |
Why?
|
| Abortion, Spontaneous | 6 | 2023 | 544 | 2.300 |
Why?
|
| Pregnancy, Ectopic | 3 | 2023 | 141 | 1.860 |
Why?
|
| Abortifacient Agents, Steroidal | 6 | 2023 | 19 | 1.820 |
Why?
|
| Intrauterine Devices | 4 | 2023 | 122 | 1.750 |
Why?
|
| Intrauterine Devices, Medicated | 3 | 2023 | 28 | 1.690 |
Why?
|
| Intrauterine Devices, Copper | 2 | 2023 | 32 | 1.550 |
Why?
|
| Chorionic Gonadotropin | 5 | 2023 | 477 | 1.350 |
Why?
|
| Contraceptive Agents, Female | 4 | 2023 | 135 | 1.220 |
Why?
|
| Abortion, Legal | 5 | 2022 | 116 | 1.220 |
Why?
|
| Vacuum Curettage | 4 | 2018 | 48 | 1.070 |
Why?
|
| Pregnancy Trimester, First | 10 | 2023 | 853 | 1.020 |
Why?
|
| Pregnancy | 49 | 2023 | 29144 | 0.980 |
Why?
|
| Pregnancy Tests | 1 | 2023 | 30 | 0.890 |
Why?
|
| Anesthetics, Intravenous | 3 | 2018 | 417 | 0.870 |
Why?
|
| Dilatation | 4 | 2023 | 291 | 0.810 |
Why?
|
| Pregnancy Trimester, Second | 6 | 2023 | 732 | 0.810 |
Why?
|
| Conscious Sedation | 3 | 2018 | 528 | 0.790 |
Why?
|
| Lacerations | 1 | 2022 | 144 | 0.770 |
Why?
|
| Minors | 2 | 2022 | 50 | 0.720 |
Why?
|
| Abortion, Therapeutic | 3 | 2016 | 35 | 0.720 |
Why?
|
| Parental Consent | 1 | 2019 | 62 | 0.670 |
Why?
|
| Analgesia | 3 | 2013 | 461 | 0.610 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 114 | 0.600 |
Why?
|
| Pregnancy in Adolescence | 1 | 2019 | 158 | 0.600 |
Why?
|
| Naproxen | 1 | 2016 | 99 | 0.560 |
Why?
|
| Labor, Induced | 2 | 2011 | 146 | 0.560 |
Why?
|
| Dilatation and Curettage | 1 | 2015 | 56 | 0.530 |
Why?
|
| Ibuprofen | 2 | 2013 | 236 | 0.470 |
Why?
|
| Labor Stage, First | 1 | 2013 | 20 | 0.470 |
Why?
|
| Ketorolac | 1 | 2013 | 79 | 0.450 |
Why?
|
| Oxytocics | 2 | 2003 | 68 | 0.450 |
Why?
|
| Laminaria | 3 | 2015 | 4 | 0.430 |
Why?
|
| Aftercare | 2 | 2020 | 866 | 0.410 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 371 | 0.400 |
Why?
|
| Levonorgestrel | 2 | 2023 | 77 | 0.380 |
Why?
|
| Obstetric Labor Complications | 1 | 2013 | 238 | 0.380 |
Why?
|
| Administration, Intravaginal | 5 | 2016 | 150 | 0.380 |
Why?
|
| Men | 1 | 2010 | 63 | 0.360 |
Why?
|
| Pain | 4 | 2023 | 4986 | 0.350 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2010 | 113 | 0.350 |
Why?
|
| Female | 56 | 2023 | 380194 | 0.350 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 230 | 0.340 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2016 | 162 | 0.340 |
Why?
|
| Massachusetts | 9 | 2023 | 8663 | 0.340 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 188 | 0.340 |
Why?
|
| Midazolam | 3 | 2018 | 270 | 0.330 |
Why?
|
| Fetal Death | 1 | 2011 | 448 | 0.330 |
Why?
|
| Spouse Abuse | 1 | 2010 | 178 | 0.330 |
Why?
|
| Cervical Ripening | 2 | 2005 | 18 | 0.330 |
Why?
|
| Terminology as Topic | 1 | 2015 | 1547 | 0.320 |
Why?
|
| Contraceptives, Postcoital | 1 | 2007 | 16 | 0.320 |
Why?
|
| Pregnancy, Unwanted | 1 | 2007 | 26 | 0.310 |
Why?
|
| Contraception, Postcoital | 1 | 2007 | 22 | 0.310 |
Why?
|
| Fentanyl | 3 | 2018 | 410 | 0.310 |
Why?
|
| Young Adult | 20 | 2023 | 56430 | 0.300 |
Why?
|
| Reminder Systems | 1 | 2010 | 371 | 0.300 |
Why?
|
| Postpartum Period | 2 | 2011 | 1086 | 0.300 |
Why?
|
| Social Stigma | 3 | 2018 | 701 | 0.290 |
Why?
|
| Pregnancy, Unplanned | 1 | 2007 | 95 | 0.290 |
Why?
|
| Hysteroscopy | 1 | 2007 | 102 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2282 | 0.280 |
Why?
|
| Uterine Diseases | 1 | 2007 | 135 | 0.280 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2065 | 0.270 |
Why?
|
| Sexual Partners | 1 | 2010 | 730 | 0.270 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 2795 | 0.250 |
Why?
|
| Ultrasonography | 3 | 2013 | 5985 | 0.250 |
Why?
|
| Adult | 31 | 2023 | 214055 | 0.240 |
Why?
|
| Rh Isoimmunization | 1 | 2023 | 21 | 0.240 |
Why?
|
| Humans | 56 | 2023 | 744343 | 0.240 |
Why?
|
| Double-Blind Method | 6 | 2016 | 12026 | 0.230 |
Why?
|
| Contraception | 3 | 2020 | 359 | 0.230 |
Why?
|
| Retrospective Studies | 12 | 2023 | 77449 | 0.230 |
Why?
|
| Pain Measurement | 4 | 2018 | 3420 | 0.230 |
Why?
|
| Body Mass Index | 2 | 2018 | 12720 | 0.220 |
Why?
|
| Administration, Oral | 4 | 2016 | 3913 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2012 | 3022 | 0.210 |
Why?
|
| Adolescent | 16 | 2020 | 85781 | 0.200 |
Why?
|
| Midwifery | 1 | 2003 | 132 | 0.200 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1590 | 0.190 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 1162 | 0.190 |
Why?
|
| Anesthetics | 1 | 2006 | 539 | 0.180 |
Why?
|
| Gestational Age | 6 | 2023 | 3493 | 0.180 |
Why?
|
| Faculty | 1 | 2023 | 386 | 0.180 |
Why?
|
| Cervix Uteri | 1 | 2003 | 590 | 0.170 |
Why?
|
| Patient Satisfaction | 6 | 2018 | 3396 | 0.170 |
Why?
|
| Medication Adherence | 1 | 2010 | 2063 | 0.170 |
Why?
|
| Time Factors | 9 | 2016 | 40075 | 0.160 |
Why?
|
| Curriculum | 2 | 2023 | 3605 | 0.150 |
Why?
|
| Outpatients | 2 | 2023 | 1486 | 0.150 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 162 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 432 | 0.140 |
Why?
|
| Desogestrel | 1 | 2016 | 23 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2006 | 1643 | 0.140 |
Why?
|
| Injections, Intramuscular | 2 | 2016 | 552 | 0.140 |
Why?
|
| Pregnancy Rate | 3 | 2016 | 643 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2016 | 2618 | 0.140 |
Why?
|
| Professional Practice Location | 1 | 2015 | 59 | 0.130 |
Why?
|
| Professional Role | 1 | 2018 | 306 | 0.130 |
Why?
|
| Gender Identity | 1 | 2021 | 688 | 0.130 |
Why?
|
| Obesity | 1 | 2017 | 12745 | 0.130 |
Why?
|
| Estradiol | 1 | 2002 | 2020 | 0.130 |
Why?
|
| Erythrocytes | 1 | 2023 | 2455 | 0.120 |
Why?
|
| Surgical Instruments | 1 | 2015 | 395 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 2274 | 0.110 |
Why?
|
| Treatment Outcome | 9 | 2018 | 63114 | 0.100 |
Why?
|
| Prevalence | 3 | 2023 | 15226 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 13408 | 0.100 |
Why?
|
| Cross Infection | 1 | 2020 | 1416 | 0.100 |
Why?
|
| Communication Aids for Disabled | 1 | 2010 | 56 | 0.090 |
Why?
|
| Coercion | 1 | 2010 | 63 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 40561 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2023 | 53288 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2708 | 0.090 |
Why?
|
| Telemetry | 1 | 2010 | 205 | 0.080 |
Why?
|
| Poverty Areas | 1 | 2010 | 275 | 0.080 |
Why?
|
| Nurses | 1 | 2018 | 2461 | 0.080 |
Why?
|
| Health Policy | 1 | 2020 | 2661 | 0.080 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2007 | 73 | 0.080 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 146 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2015 | 2250 | 0.070 |
Why?
|
| Education, Medical | 1 | 2018 | 1721 | 0.070 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 968 | 0.070 |
Why?
|
| Language | 1 | 2015 | 1471 | 0.070 |
Why?
|
| United States | 7 | 2023 | 69872 | 0.070 |
Why?
|
| Tissue Adhesions | 1 | 2007 | 235 | 0.070 |
Why?
|
| Women | 1 | 2007 | 230 | 0.070 |
Why?
|
| Lorazepam | 1 | 2006 | 145 | 0.070 |
Why?
|
| United States Food and Drug Administration | 2 | 2003 | 1584 | 0.070 |
Why?
|
| Students, Medical | 1 | 2018 | 1862 | 0.060 |
Why?
|
| Intraoperative Period | 1 | 2005 | 520 | 0.060 |
Why?
|
| Patient Preference | 1 | 2011 | 890 | 0.060 |
Why?
|
| San Francisco | 1 | 2004 | 159 | 0.060 |
Why?
|
| Informed Consent | 1 | 2010 | 995 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21746 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3843 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2007 | 1183 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 255 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2003 | 600 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 711 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 25043 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 881 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2004 | 662 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 933 | 0.040 |
Why?
|
| Oxytocin | 1 | 2003 | 394 | 0.040 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 151 | 0.040 |
Why?
|
| Federal Government | 1 | 2020 | 260 | 0.040 |
Why?
|
| Depersonalization | 1 | 2018 | 39 | 0.040 |
Why?
|
| Administration, Buccal | 2 | 2008 | 12 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 6489 | 0.040 |
Why?
|
| Medical Records | 1 | 2004 | 1413 | 0.040 |
Why?
|
| Placebos | 1 | 2002 | 1676 | 0.040 |
Why?
|
| State Government | 1 | 2020 | 372 | 0.040 |
Why?
|
| Algorithms | 1 | 2018 | 13881 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2016 | 23338 | 0.040 |
Why?
|
| Boston | 1 | 2010 | 9313 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39050 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2006 | 6459 | 0.040 |
Why?
|
| Decision Making | 1 | 2010 | 3887 | 0.030 |
Why?
|
| Checklist | 1 | 2023 | 833 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2018 | 392 | 0.030 |
Why?
|
| Risk Factors | 4 | 2020 | 72290 | 0.030 |
Why?
|
| Equipment Design | 1 | 2004 | 3582 | 0.030 |
Why?
|
| Middle Aged | 3 | 2018 | 213383 | 0.030 |
Why?
|
| Women's Health | 1 | 2003 | 2034 | 0.030 |
Why?
|
| Reoperation | 1 | 2004 | 4201 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2002 | 2684 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 5137 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3610 | 0.030 |
Why?
|
| Risk | 1 | 2023 | 9687 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 3923 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2016 | 2971 | 0.020 |
Why?
|
| Burnout, Professional | 1 | 2018 | 694 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3508 | 0.020 |
Why?
|
| Child | 1 | 2017 | 77709 | 0.020 |
Why?
|
| Magnesium Sulfate | 1 | 2007 | 68 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2007 | 74 | 0.020 |
Why?
|
| Administration, Rectal | 1 | 2006 | 73 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 9959 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 153 | 0.020 |
Why?
|
| El Salvador | 1 | 2005 | 39 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2020 | 5102 | 0.020 |
Why?
|
| Telemedicine | 1 | 2020 | 2872 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2011 | 2682 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1654 | 0.010 |
Why?
|
| Education | 1 | 2005 | 543 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8388 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 15295 | 0.010 |
Why?
|
| Polymers | 1 | 2007 | 1621 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2007 | 1736 | 0.010 |
Why?
|
| Male | 2 | 2018 | 350118 | 0.010 |
Why?
|
| Educational Status | 1 | 2005 | 2540 | 0.010 |
Why?
|